These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31004652)

  • 21. Quantifying electrostatic interactions in pharmaceutical solid systems.
    Rowley G
    Int J Pharm; 2001 Oct; 227(1-2):47-55. PubMed ID: 11564540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler.
    Yeung S; Traini D; Tweedie A; Lewis D; Church T; Young PM
    AAPS PharmSciTech; 2019 Jan; 20(3):94. PubMed ID: 30690674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical stability of dry powder inhaler formulations.
    Shetty N; Cipolla D; Park H; Zhou QT
    Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
    [No Abstract]   [Full Text] [Related]  

  • 24. Performance of an acoustically mixed pharmaceutical dry powder delivered from a novel inhaler.
    Tanaka R; Takahashi N; Nakamura Y; Hattori Y; Ashizawa K; Otsuka M
    Int J Pharm; 2018 Mar; 538(1-2):130-138. PubMed ID: 29341919
    [No Abstract]   [Full Text] [Related]  

  • 25. Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.
    Boc S; Momin MAM; Farkas DR; Longest W; Hindle M
    AAPS PharmSciTech; 2021 Apr; 22(4):135. PubMed ID: 33860378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin.
    Barazesh A; Gilani K; Rouini M; Barghi MA
    Daru; 2020 Jun; 28(1):75-85. PubMed ID: 31808069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure.
    Leung CMS; Tong Z; Zhou QT; Chan JGY; Tang P; Sun S; Yang R; Chan HK
    AAPS J; 2016 Sep; 18(5):1159-1167. PubMed ID: 27161214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of a One-Dimensional Computational Model for the Prediction of Deposition from a Dry Powder Inhaler.
    Gourgoulianis K; Daniil Z; Athanasiou K; Rozou S; Bontozoglou V
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):435-443. PubMed ID: 28683222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of electrostatic charge decay in pharmaceutical powders and polymer materials used in dry powder inhaler devices.
    Carter PA; Rowley G; Fletcher EJ; Stylianopoulos V
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1083-8. PubMed ID: 9876564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applications of capsule dosing techniques for use in dry powder inhalers.
    Edwards D
    Ther Deliv; 2010 Jul; 1(1):195-201. PubMed ID: 22816126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advancement of a Positive-Pressure Dry Powder Inhaler for Children: Use of a Vertical Aerosolization Chamber and Three-Dimensional Rod Array Interface.
    Farkas D; Bonasera S; Bass K; Hindle M; Longest PW
    Pharm Res; 2020 Aug; 37(9):177. PubMed ID: 32862295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modification of electrostatic charge on inhaled carrier lactose particles by addition of fine particles.
    Bennett FS; Carter PA; Rowley G; Dandiker Y
    Drug Dev Ind Pharm; 1999 Jan; 25(1):99-103. PubMed ID: 10028425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Particle size and charge distribution analysis of pharmaceutical aerosols generated by inhalers.
    Saini D; Biris AS; Srirama PK; Mazumder MK
    Pharm Dev Technol; 2007; 12(1):35-41. PubMed ID: 17484142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders.
    Sun Y; Cui Z; Sun Y; Qin L; Zhang X; Liu Q; Shen X; Yu D; Mao S
    Int J Pharm; 2020 Oct; 588():119798. PubMed ID: 32828976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of factors affecting electrostatic charging of pharmaceuticals and adhesive mixtures for inhalation.
    Kaialy W
    Int J Pharm; 2016 Apr; 503(1-2):262-76. PubMed ID: 26836710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
    Wauthoz N; Hennia I; Ecenarro S; Amighi K
    Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.
    Behara SR; Farkas DR; Hindle M; Longest PW
    Pharm Res; 2014 Feb; 31(2):360-72. PubMed ID: 23949304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.